Medexus Pharmaceuticals (TSE:MDP) Stock Rating Upgraded by Raymond James

Medexus Pharmaceuticals (TSE:MDP) was upgraded by stock analysts at Raymond James from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports. The firm presently has a C$4.00 target price on the stock, up from their previous target price of C$3.00. Raymond James’ price objective points to a potential upside of 87.79% from the company’s previous close. Raymond James also issued estimates for Medexus Pharmaceuticals’ FY2029 earnings at $0.89 EPS.

MDP has been the topic of several other reports. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Finally, Stifel Nicolaus lifted their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Trading Down 0.9 %

MDP opened at C$2.13 on Wednesday. The stock has a market capitalization of C$52.25 million, a P/E ratio of 43.20 and a beta of 1.96. The stock has a 50-day moving average price of C$2.47 and a 200-day moving average price of C$2.19. Medexus Pharmaceuticals has a 12-month low of C$1.44 and a 12-month high of C$3.16.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.